Recent and new targets for small molecule anti-cancer agents

Drug Discovery Today: Technologies

Volumn 6, Issue 1-4, 2009, Pages

  Ovaa, Huib ^a   Kuijl, Coenraad ^a   Neefjes, Jacques ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AMINOPTERIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; FINASTERIDE; FLUOROURACIL; FOLIC ACID; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LONAFARNIB; MELPHALAN; METHOTREXATE; MK 0752; OLAPARIB; PACLITAXEL; RAPAMYCIN; SUNITINIB; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COMPETITIVE INHIBITION; CUTANEOUS T CELL LYMPHOMA; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; HUMAN; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77957871791     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.01.001     Document Type: Review

References (63)

1. L.S. Goodman Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta- chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan JAMA 251 1984 2255 2261
2. W. Sneader Drug Discovery: A History 2005 Wiley
3. S. Farber The action of pteroylglutamic conjugates on man Science 106 1947 619 621
4. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N. Engl. J. Med. 238 1948 787 793
5. N.K. Chaudhuri Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo Cancer Res. 18 1958 318 328
6. A. Dimarco 'Daunomycin', a new antibiotic of the rhodomycin group Nature 201 1964 706 707
7. C.A. Frederick Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin Biochemistry 29 1990 2538 2549
8. F.A. Fornari Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol Pharmacol 45 1994 649 656
9. M.E.W. Wall Plant antitumor agents I. Isolation and structure of camtothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata J. Am. Chem. Soc. 88 1966 3
10. Y. Pommier DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition Chem. Rev. 109 2009 2894 2902
11. B. Rosenberg Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698 699
12. D.A. Fuchs, and R.K. Johnson Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison Cancer Treat. Rep. 62 1978 1219 1222
13. M.C. Wani Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J. Am. Chem. Soc. 93 1971 2325 2327
14. R.C. Donehower Phase I trial of taxol in patients with advanced cancer Cancer Treat. Rep. 71 1987 1171 1177
15. J. Goodman, and V. Walsh The Story of Taxol: Nature and Politics in the Pursuit of an Anti-cancer Drug 2001 Cambridge University Press
16. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat Rev Drug Discov 2 2003 205 213
17. R. Michalides Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer Cancer Cell 5 2004 597 605
18. S.A. Krum Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival EMBO J 27 2008 535 545
19. W. Zwart Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha Mol. Cancer Ther. 6 2007 1526 1533
20. D. Ghosh Structural basis for androgen specificity and oestrogen synthesis in human aromatase Nature 457 2009 219 223
21. N. Fleshner, and A.R. Zlotta Prostate cancer prevention: past, present, and future Cancer 110 2007 1889 1899
22. S.K. Hanks The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
23. S.K. Hanks, and T. Hunter Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification FASEB J. 9 1995 576 596
24. C. Kuijl Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 Nature 450 2007 725 730
25. H. Reuveni Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design Biochemistry 41 2002 10304 10314
26. D.D. Sarbassov Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
27. A. Quintas-Cardama Flying under the radar: the new wave of BCR-ABL inhibitors Nat. Rev. Drug Discov. 6 2007 834 848
28. R. Tanaka, and S. Kimura Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation Expert Rev. Anticancer Ther. 8 2008 1387 1398
29. M.C. Heinrich Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J. Clin. Oncol. 20 2002 1692 1703
30. M. Soda Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
31. T.F. Franke The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase Cell 81 1995 727 736
32. I.C. Gray Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN Br. J. Cancer 78 1998 1296 1300
33. E. Hannak Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans J. Cell Biol. 155 2001 1109 1116
34. R. Giet, and D.M. Glover Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis J. Cell Biol. 152 2001 669 682
35. M.A. Hardwicke GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models Mol. Cancer Ther. 8 2009 1808 1817
36. C.L. Arteaga EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans Cancer Cell 9 2006 421 423
37. L. Coussens Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1985 1132 1139
38. D.R. Senger Vascular permeability factor (VPF, VEGF) in tumor biology Cancer Metastasis Rev. 12 1993 303 324
39. T.J. Lynch Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
40. P. Stephens Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525 526
41. L. Sun Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)- ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 46 2003 1116 1119 (Pubitemid 36428215)
42. A. Kalikaki Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br. J. Cancer 99 2008 923 929
43. L. Zhang Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties Oncogene 16 1998 2855 2863
44. P.G. Richardson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617
45. R.E. Amir The NEDD8 pathway is essential for SCF(beta-TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105 J. Biol. Chem. 277 2002 23253 23259
46. T.A. Soucy An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Nature 458 2009 732 736
47. A. Garg, and B.B. Aggarwal Nuclear transcription factor-kappaB as a target for cancer drug development Leukemia 16 2002 1053 1068
48. D. Chauhan A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 2005 407 419 (Pubitemid 41579835)
49. R. Piva CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood 111 2008 2765 2775
50. H.J. Zhou Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 52 2009 3028 3038
51. J.M. Ray, and W.G. Stetler-Stevenson The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis Eur. Respir. J. 7 1994 2062 2072
52. B. Fingleton Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects Expert Opin. Ther. Targets 7 2003 385 397
53. E.H. Schroeter Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain Nature 393 1998 382 386
54. M. Shih Ie, and T.L. Wang Notch signaling, gamma-secretase inhibitors, and cancer therapy Cancer Res. 67 2007 1879 1882
55. S.M. Thomas Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases Cell 68 1992 1031 1040
56. K.L. Dunn The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling Biochem. Cell Biol. 83 2005 1 14
57. L. Sistonen, and K. Alitalo Activation of c-ras oncogenes by mutations and amplification Ann. Clin. Res. 18 1986 297 303
58. F.G. Njoroge (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl] -1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent J. Med. Chem. 41 1998 4890 4902
59. P.C. Fong Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
60. S.M. Huang Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 461 2009 614 620
61. N. Barker The Yin-Yang of TCF/beta-catenin signaling Adv. Cancer Res. 77 2000 1 24
62. T. Guastafierro CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery J. Biol. Chem. 283 2008 21873 21880
63. N.P. Dantuma A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling J. Cell Biol. 173 2006 19 26